BIOTIE THERAPIES CORP. Stock Exchange Release 30
July 2014 at 8.45 am
Change in the number of votes relating to Biotie Therapies Corp.'s shares
Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares
held as treasury shares, that were issued on 2 January 2014, pursuant to the
Stock Option Plan 2011 and the Equity Incentive Plan 2011 (the "Plans") as
follows:
Shares Cumulative shares Remaining shares to
conveyed conveyed since 2 January 2014 be conveyed
1,812,910 3,059,160 262,500
Under the Stock Option Plan 2011, the owners of the stock options may subscribe
for a maximum total of 7,401,000 new shares in the Company or existing shares
held by the Company. A total of 766,750 shares have been subscribed for during
the period 9 May 2014 and 29 July 2014 and 766,750 of the treasury shares will
be used for these share subscriptions. The subscription price of EUR 0.01 per
share has been fully paid by the employee and the EUR 7,667.50 funds received
will be credited to the Company's reserve for non-restricted equity.
The first vesting period of the Equity Incentive Plan 2011 ended on 5 January
2014, after which the Company's shares shall be delivered to employees on the
basis of the granted share units. It was resolved pursuant to the authorization
of the Annual General Meeting of the Shareholders held on 4 April 2013 to issue
1,046,160 existing treasury shares to the employees without consideration for
the purposes of remunerating the employees pursuant to the terms and conditions
of the Equity Incentive Plan 2011 and thus, there is an especially weighty
financial reason to derogate from the pre-emptive right of the shareholders, as
referred to in Chapter 9 Section 4(1) of the Companies Act (624/2006, as
amended).
The conveyed shares previously held as treasury shares have not carried any
voting rights. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:
Increase in number Total amount of Number of the Total number
of outstanding shares voting rights Company's share held of registered
by the Group shares
1,812,190 449,515,102 6,517,296 456,032,398
Turku, 30 July 2014
Biotie Therapies Corp.
Timo Veromaa, President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media
[HUG#1842873]
Change in the number of votes relating to Biotie Therapies Corp.'s shares
| Source: Biotie Therapies